The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Neurotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System
Open accessAbstract
Myelin of the adult CNS is vulnerable to a variety of metabolic, toxic, and autoimmune insults. That remyelination can ensue, following demyelinating insult, has been well demonstrated. Details of the process of remyelination are, however difficult to ascertain since in most experimental models of demyelination/remyelination the severity, localization of lesion site, or time course of the pathophysiology is variable from animal to animal. In contrast, an experimental model in which massive demyelination can be reproducibly induced in large areas of mouse brain is exposure to the copper chelator, cuprizone, in the diet. We review work from several laboratories over the past 3 decades, with emphasis on our own recent studies, which suggest an overall picture of cellular events involved in demyelination/remyelination. When 8 week old C57BL/6 mice are fed 0.2% cuprizone in the diet, mature olidgodendroglia are specifically insulted (cannot fulfill the metabolic demand of support of vast amounts of myelin) and go through apoptosis.This is closely followed by recruitment of microglia and phagoctytosis of myelin. Studies of myelin gene expression, coordinated with morphological studies, indicate that even in the face of continued metabolic challenge, oligodendroglial progenitor cells proliferate and invade demyelinated areas. If the cuprizone challenge is terminated, an almost complete remyelination takes place in a matter of weeks. Communication between different cell types by soluble factors may be inferred. This material is presented in the context of a model compatible with present data—and which can be tested more rigorously with the cuprizone model. The reproducibility of the model indicates that it may allow for testing of manipulations (e.g. available knockouts or transgenics on the common genetic background, or pharmacological treatments) which may accelerate or repress the process of demyelination and or remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The C57BL/6 mice showed a dramatic loss of myelin staining at this time point (Fig. 1b), which is consistent with previous reports [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon treatment with cuprizone, mice typically exhibit profound demyelination in the corpus callosum, the cortex and the superior cerebellar peduncles [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most investigators use the standard C57BL/6 mouse strain in the cuprizone model to study the different molecular components involved in the complex pathogenic processes leading to corpus callosum demyelination [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the corpus callosum, apoptosis of oligodendrocytes is observed, together with recruitment of microglia/macrophages, astrocytes and oligodendrocyte progenitor cells (OPCs) [5, 6].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a pattern of two cycles of demyelination and remyelination, followed by chronic demyelination from which animals do not recover 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, C57BL/6 mice experience a spontaneous partial remyelination after 6 weeks and then continue to demyelinate further when exposed continuously to cuprizone 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, unlike microglia and astrocytes in C57BL/6 mice that respond vigorously to demyelination 2, 23, 39, these cell types in SJL mice have a guarded response at midline and in the lateral region, which correlates with subdued demyelination.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cuprizone toxicity produces profound demyelination in the white and grey matter of the brain that mirrors sites of MS pathology [46].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other features common to both cuprizone-induced and type 3 MS lesions are mitochondrial stress, selective loss of myelin-associated glycoprotein (MAG), lesions with indistinct borders that are not perivascular, pronounced glial activation, and lymphocyte infiltration [43, 46, 65, 69–71].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histopathological hallmark of the cuprizone model as standardized by Hiremath is oligodendrocyte death and subsequent demyelination in the corpus callosum, superior cerebellar peduncles, hippocampus [42, 46–54] and several other areas of the mouse brain (reviewed in [20]).”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial activation and axonal loss positively correlate with demyelination and the reproducible lesion localization – primarily in the corpus callosum [186], cerebellar peduncle [186], hippocampus [187], and cortex [184, 185, 188] – mirrors the topographical specificity of MS pathology, including subpial cortical demyelination seen in PMS patients.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remyelination is very robust in the cuprizone model and starts directly after demyelination is complete, irrespective if cuprizone is further fed or not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depletion of microglia likewise prevented the loss of oligodendrocytes (OLs) in the CC that normally results from CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The cuprizone model involves administration of the toxin cuprizone to induce oligodendrocyte apoptosis [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Here, we explored the effect of antibody-mediated TREM2 activation on microglia in a well-established toxin-induced model of demyelination in the CNS resulting from exposure to the copper chelator cuprizone (CPZ) in the diet [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“These events lead to OPC recruitment, differentiation into mature OLs, and then remyelination which is almost complete within few weeks from toxin withdrawal [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It may suggest that NODDI could be sensitive biomarkers to probe the different stages of white matter pathology between acute demyelination and chronic demyelination (Matsushima and Morell 2001).”
From Neurite orientation dispersion and density imaging of mouse brain microstructure (2019) · cites this paper as Matsushima and Morell 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Historically these cells are not linked to demyelination following cuprizone treatment because the loss of the V(D)J recombination activation gene-1 (RAG-1), which is critical for B- and T- lymphocyte generation [269], does not alter demyelination and T-cell accumulation in the corpus callosum [46, 270].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Demyelination peaks between 4.5 and 5 weeks of cuprizone exposure in the CC and between 5 and 6 weeks in the cortex and hippocampus (Hiremath et al., 1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi et al., 2009; Koutsoudaki et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Strong astrogliosis comprising hypertrophy and hyperplasia of astrocytes occurs as a response to cuprizone treatment in different white and gray matter structures for instance the CC (Matsushima and Morell, 2001; Gudi et al., 2009), hippocampus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum, cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Astrogliosis is an additional pathological hallmark of CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412
Self-citation(1978) · PubMed · Cited by 297
Nishiyama, A., Lin, X., Giese, N. A., Heldin, C., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3 · Cited by 244
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Self-citationKomoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Blakemore, W. F. (1972) · Journal of Neurocytology · doi:10.1007/bf01102943 · Cited by 217
Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination
Morell, P., Barrett, C. V., Mason, J. L., Toews, A. D., Hostettler, J. D., Knapp, G. W., & Matsushima, G. K. (1998) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1998.0715 · Cited by 213
Self-citationDemyelination of the superior cerebellar peduncle in the mouse induced by cuprizone
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90118-4 · Cited by 207
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90119-6 · Cited by 177
Research works printed but not linked: 2
- Jurevics HA, 2000, Lipid metabolism during remyelination in brain, J Neurochem, 74, S32
- Ludwin SK, 1980, Chronic demyelination inhibits remyelination in the central nervous system, Lab Invest, 43, 382
Cited by
Sorted by citations
Items 201–300 of 985
Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
Xiao, L., Guo, D., Hu, C., Shen, W., Shan, L., Li, C., Liu, X., Yang, W., Zhang, W., & He, C. (2012) · Glia · doi:10.1002/glia.22333 · Cited by 78
Soundarapandian, M. M., Selvaraj, V., Lo, U.-G., Golub, M. S., Feldman, D. H., Pleasure, D. E., & Deng, W. (2011) · Scientific Reports · doi:10.1038/srep00002 · Cited by 75
Yang, H.-J., Wang, H., Zhang, Y., Xiao, L., Clough, R. W., Browning, R., Li, X.-M., & Xu, H. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.011 · Cited by 75
McMahon, E. J., Cook, D. N., Suzuki, K., & Matsushima, G. K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2964 · Cited by 75
Self-citationMitochondrial dysfunction in central nervous system white matter disorders
Morató, L., Bertini, E., Verrigni, D., Ardissone, A., Ruíz, M., Ferrer, I., Uziel, G., & Pujol, A. (2014) · Glia · doi:10.1002/glia.22670 · Cited by 77
Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis
Schneider, A., Araújo, G. W., Trajković, K., Herrmann, M. M., Merkler, D., Mandelkow, E., Weissert, R., & Simons, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409954200 · Cited by 72
Cuprizone neurotoxicity, copper deficiency and neurodegeneration
Benetti, F., Ventura, M., Salmini, B., Ceola, S., Carbonera, D., Mammi, S., Zitolo, A., D’Angelo, P., Urso, E., & Maffia, M. (2010) · NeuroToxicology · doi:10.1016/j.neuro.2010.05.008 · Cited by 74
Luo, F., Herrup, K., Qi, X., & Yang, Y. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.02.015 · Cited by 74
Titus, H. E., Chen, Y., Podojil, J. R., Robinson, A. P., Balabanov, R. D., Popko, B., & Miller, S. D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.599717 · Cited by 88
Cate, H. S., Sabo, J. K., Merlo, D., Kemper, D., Aumann, T. D., Robinson, J., Merson, T. D., Emery, B., Perreau, V. M., & Kilpatrick, T. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06660.x · Cited by 76
Patel, R., Moore, S. M., Crawford, D. K., Hannsun, G., Manda, S. V., Tan, K. M., Molaie, D. M., & Tiwari-Woodruff, S. K. (2013) · Brain Pathology · doi:10.1111/bpa.12029 · Cited by 75
Crawford, D. K., Mangiardi, M., & Tiwari-Woodruff, S. K. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.05.013 · Cited by 73
Galectin-3 controls the response of microglial cells to limit cuprizone-induced demyelination
Hoyos, H. C., Rinaldi, M., Méndez‐Huergo, S. P., Marder, M., Rabinovich, G. A., Pasquini, J. M., & Pasquini, L. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.023 · Cited by 79
Moharregh-Khiabani, D., Blank, A., Skripuletz, T., Miller, E., Kotsiari, A., Gudi, V., & Stangel, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011769 · Cited by 74
Vitamin C promotes oligodendrocytes generation and remyelination
Guo, Y., Suo, N., Cui, X. J., Yuan, Q., & Xie, X. (2018) · Glia · doi:10.1002/glia.23306 · Cited by 79
GAS6 Enhances Repair Following Cuprizone-Induced Demyelination
Tsiperson, V., Li, X., Schwartz, G. J., Raine, C. S., & Shafit‐Zagardo, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015748 · Cited by 71
Zaaraoui, W., Deloire, M., Merle, M., Girard, C., Raffard, G., Biran, M., Inglese, M., Petry, K. G., Gonen, O., Brochet, B., et al. (2008) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-008-0141-3 · Cited by 75
Schultz, V., van der Meer, F., Wrzos, C., Scheidt, U., Bahn, E., Stadelmann, C., Brück, W., & Junker, A. (2017) · Glia · doi:10.1002/glia.23167 · Cited by 75
Kuboyama, K., Fujikawa, A., Suzuki, R., & Noda, M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2127-15.2015 · Cited by 68
Mediators of oligodendrocyte differentiation during remyelination
Patel, J. R., & Klein, R. S. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.037 · Cited by 76
Harnessing the integrated stress response for the treatment of multiple sclerosis
Way, S. W., & Popko, B. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00381-6 · Cited by 71
Oligodendroglia and neurotrophic factors in neurodegeneration
Bankston, A. N., Mandler, M. D., & Feng, Y. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1321-3 · Cited by 76
An Alternative Cuprizone-Induced Demyelination and Remyelination Mouse Model
Wei, Z. C., Liu, A., Lu, J., Zhang, W., Tattersall, D., & Wang, J. (2017) · ASN NEURO · doi:10.1177/1759091417725174 · Cited by 71
Neurite orientation dispersion and density imaging of mouse brain microstructure
Wang, N., Zhang, J., Cofer, G., Qi, Y., Anderson, R. J., White, L. E., & Allan Johnson, G. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01877-x · Cited by 69
Psenicka, M. W., Smith, B. C., Tinkey, R. A., & Williams, J. L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.654284 · Cited by 73
Biancotti, J. C., Kumar, S., & de Vellis, J. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9792-8 · Cited by 69
In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination
Merrill, J. E. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.145 · Cited by 72
Ma, G. Z. M., Stankovich, J. M., Kilpatrick, T. J., Binder, M. D., & Field, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016964 · Cited by 70
Dupree, J. L., Mason, J. L., Marcus, J., Stull, M., Levinson, R., Matsushima, G. K., & Popko, B. (2004) · Neuron Glia Biology · doi:10.1017/s1740925x04000304 · Cited by 75
Self-citationUlrich, R., Seeliger, F., Kreutzer, M., Germann, P., & Baumgärtner, W. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00956.x · Cited by 68
Chen, M., & Guilarte, T. R. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj172 · Cited by 70
Geva, M., Cabilly, Y., Assaf, Y., Mindroul, N., Marom, L., Raini, G., Pinchasi, D., & Elroy‐Stein, O. (2010) · Brain · doi:10.1093/brain/awq180 · Cited by 70
A Novel Fluorescent Probe That Is Brain Permeable and Selectively Binds to Myelin
Wu, C., Tian, D., Feng, Y., Polak, P. E., Wei, J., Sharp, A., Stankoff, B., Lubetzki, C., Zalc, B., Mufson, E. J., et al. (2006) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.5a6901.2006 · Cited by 68
Tsiperson, V., Huang, Y., Bagayogo, I. P., Song, Y. J., VonDran, M. W., DiCicco-Bloom, E. M., & Dreyfus, C. F. (2015) · ASN NEURO · doi:10.1177/1759091414566878 · Cited by 66
Chronic demyelination-induced seizures
Lapato, A. S., Szu, J. I., Hasselmann, J., Khalaj, A. J., Binder, D. K., & Tiwari-Woodruff, S. K. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.01.035 · Cited by 66
Donepezil, a drug for Alzheimer’s disease, promotes oligodendrocyte generation and remyelination
Cui, X. J., Guo, Y., Fang, J., Shi, C., Suo, N., Zhang, R., & Xie, X. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0206-4 · Cited by 68
Myelin copper and the cuprizone model of schizophrenia
Konradi, C. L. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s129 · Cited by 68
Olah, M., Ping, G., Haas, A. H. D., Brouwer, N., Meerlo, P., van der Zee, E. A., Biber, K. P. H., & Boddeke, H. W. G. M. (2008) · Glia · doi:10.1002/glia.20828 · Cited by 66
Kataria, H., Alizadeh, A., Shahriary, G. M., Rizi, S. S., Henrie, R., Santhosh, K. T., Thliveris, J. A., & Karimi‐Abdolrezaee, S. (2017) · Glia · doi:10.1002/glia.23264 · Cited by 72
Tezuka, T., Tamura, M., Kondo, M. A., Sakaue, M., Okada, K., Takemoto, K., Fukunari, A., Miwa, K., Ohzeki, H., Kano, S.-I., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.07.003 · Cited by 64
Androgen Therapy in Neurodegenerative Diseases
Bianchi, V. E., Rizzi, L., Bresciani, E., Omeljaniuk, R. J., & Torsello, A. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa120 · Cited by 69
Chapman, T. W., Olveda, G. E., Bame, X., Pereira, E., & Hill, R. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01271-1 · Cited by 66
Barclay, K. M., Abduljawad, N., Cheng, Z., Kim, M. W., Zhou, L., Yang, J., Rustenhoven, J., Mazzitelli, J. A., Smyth, L. C. D., Kapadia, D., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.05.005 · Cited by 65
A mouse model for testing remyelinating therapies
Bai, C. B., Sun, H. S., Roholt, A., Benson, E. K., Edberg, D. D., Medicetty, S., Dutta, R., Kidd, G. J., Macklin, W. B., & Trapp, B. D. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.033 · Cited by 68
Generation of Demyelination Models by Targeted Ablation of Oligodendrocytes in the Zebrafish CNS
Chung, A.-Y., Kim, P.-S., Kim, S., Kim, E., Kim, D., Jeong, I., Kim, H., Ryu, J.-H., Kim, C., Choi, J., et al. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0087-9 · Cited by 66
Cell‐Specific Trafficking Suggests a new role for Renal ATP7B in the Intracellular Copper Storage
Barnes, N. L., Bartee, M. Y., Braiterman, L., Gupta, A., Ustiyan, V., Zuzel, V., Kaplan, J. H., Hubbard, A. L., & Lutsenko, S. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00901.x · Cited by 64
Differential roles of resident microglia and infiltrating monocytes in murine CNS autoimmunity
Shemer, A., & Jung, S. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0519-z · Cited by 66
iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response
Nicaise, A. M., Banda, E., Guzzo, R. M., Russomanno, K., Castro-Borrero, W., Willis, C. M., Johnson, K. M., Lo, A. C., & Crocker, S. J. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.012 · Cited by 64
Galloway, D. A., Blandford, S. N., Berry, T., Williams, J. B., Stefanelli, M., Ploughman, M., & Moore, C. S. (2019) · Glia · doi:10.1002/glia.23576 · Cited by 64
Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis
Wasko, N. J., Nichols, F. C., & Clark, R. B. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102430 · Cited by 65
Tanaka, T., Murakami, K., Bandô, Y., & Yoshida, S. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12289 · Cited by 66
Role of transmembrane semaphorin Sema6A in oligodendrocyte differentiation and myelination
Bernard, F., Moreau‐Fauvarque, C., Heitz‐Marchaland, C., Zagar, Y., Dumas, L., Fouquet, S., Lee, X., Shao, Z., Mi, S., & Chédotal, A. (2012) · Glia · doi:10.1002/glia.22378 · Cited by 65
Axl−/− mice have delayed recovery and prolonged axonal damage following cuprizone toxicity
Hoehn, H. J., Kress, Y., Sohn, A. S. W., Brosnan, C. F., Bourdon, S., & Shafit‐Zagardo, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.076 · Cited by 64
Modeling multiple sclerosis in laboratory animals
Schreiner, B., Heppner, F. L., & Becher, B. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0181-4 · Cited by 63
Cheli, V. T., González, D. A. S., Marziali, L. N., Zamora, N. N., Guitart, M. E., Spreuer, V., Pasquini, J. M., & Paez, P. M. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1447-18.2018 · Cited by 63
Zhang, Y., Bi, X., Adebiyi, O., Wang, J., Mooshekhian, A., Cohen, J., Wei, Z., Wang, F., & Li, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00332 · Cited by 62
Mandolesi, G., Bullitta, S., Fresegna, D., Vito, F. D., Rizzo, F. R., Musella, A., Guadalupi, L., Vanni, V., Bassi, M. S., Buttari, F., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.05.010 · Cited by 65
Sher, F., Boddeke, E., Olah, M., & Copray, S. C. V. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040399 · Cited by 62
Goldberg, J., Daniel, M., van Heuvel, Y., Victor, M., Beyer, C., Clarner, T., & Kipp, M. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9975-y · Cited by 62
Yoshikawa, K., Palumbo, S., Toscano, C. D., & Bosetti, F. (2011) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.04.022 · Cited by 61
Metabolic defects in multiple sclerosis
Adiele, R. C., & Adiele, C. A. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.12.005 · Cited by 62
Human Glial Progenitor Cells Effectively Remyelinate the Demyelinated Adult Brain
Windrem, M. S., Schanz, S. J., Zou, L., Chandler-Militello, D., Kuypers, N. J., Nedergaard, M., Lu, Y. Q., Mariani, J. N., & Goldman, S. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107658 · Cited by 62
17β-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss
Taylor, L. C., Puranam, K. L., Gilmore, W., Ting, J. P. ‐., & Matsushima, G. K. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.016 · Cited by 60
Self-citationAstroglial‐derived lymphotoxin‐α exacerbates inflammation and demyelination, but not remyelination
Plant, S. R., Arnett, H. A., & Ting, J. P. (2005) · Glia · doi:10.1002/glia.20089 · Cited by 60
Detection of Myelination Using a Novel Histological Probe
Xiang, Z., Nesterov, E. E., Skoch, J. M., Lin, T., Hyman, B. T., Swager, T. M., Bacskai, B. J., & Reeves, S. A. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.5a6704.2005 · Cited by 60
Islam, M. S., Tatsumi, K., Okuda, H., Shiosaka, S., & Wanaka, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.011 · Cited by 59
Petković, F., Campbell, I. L., Gonzalez, B., & Castellano, B. (2016) · Glia · doi:10.1002/glia.23043 · Cited by 59
Current advancements in promoting remyelination in multiple sclerosis
Kremer, D., Akkermann, R., Küry, P., & Dutta, R. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518800827 · Cited by 62
Lee, K. K., De Repentigny, Y., Saulnier, R., Rippstein, P., Macklin, W. B., & Kothary, R. (2006) · Glia · doi:10.1002/glia.20343 · Cited by 59
Kumar, S., Biancotti, J. C., Yamaguchi, M., & de Vellis, J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9208-6 · Cited by 60
Beneficial Effects of Minocycline on Cuprizone Induced Cortical Demyelination
Skripuletz, T., Miller, E., Moharregh-Khiabani, D., Blank, A., Pul, R., Gudi, V., Trebst, C., & Stangel, M. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0202-7 · Cited by 61
Furusho, M., Roulois, A., Franklin, R. J. M., & Bansal, R. (2015) · Glia · doi:10.1002/glia.22838 · Cited by 59
Zamora, N. N., Cheli, V. T., González, D. A. S., Wan, R., & Paez, P. M. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1644-19.2020 · Cited by 58
The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data
Vakrakou, A. G., Alexaki, A., Brinia, M.-E., Anagnostouli, M. C., Stefanis, L., & Stathopoulos, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158077 · Cited by 65
Bagchi, B., Al-Sabi, A., Kaza, S. K., Scholz, D., O’Leary, V. B., Dolly, J. O., & Ovsepian, S. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087736 · Cited by 57
Effect of high-dose 1.25 dihydroxyvitamin D3on remyelination in the cuprizone model
Nystad, A. E., Wergeland, S., Aksnes, L., Myhr, K., Bø, L., & Torkildsen, Ø. (2014) · Apmis · doi:10.1111/apm.12281 · Cited by 64
NF-κB Activation Protects Oligodendrocytes against Inflammation
Stone, S., Jamison, S., Yue, Y., Durose, W. W., Schmidt‐Ullrich, R., & Lin, W. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1608-17.2017 · Cited by 58
González, D. A. S., Cheli, V. T., Zamora, N. N., Lama, T. N., Spreuer, V., Murphy, G. G., & Paez, P. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1787-17.2017 · Cited by 56
Death receptor signalling in central nervous system inflammation and demyelination
Guire, C. M., Beyaert, R., & Loo, G. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.09.002 · Cited by 59
Abbreviated exposure to cuprizone is sufficient to induce demyelination and oligodendrocyte loss
Doan, V., Kleindienst, A. M., McMahon, E. J., Long, B. R., Matsushima, G. K., & Taylor, L. C. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23174 · Cited by 56
Self-citationGregg, J. R., Herring, N. R., Naydenov, A. V., Hanlin, R. P., & Konradi, C. L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.023 · Cited by 57
Kashani, I. R., Rajabi, Z., Akbari, M., Hassanzadeh, G., Mohseni, A., Eramsadati, M. K., Rafiee, K., Beyer, C., Kipp, M., & Zendedel, A. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3946-5 · Cited by 56
RetractedTargeting human oligodendrocyte progenitors for myelin repair
Dietz, K. C., Polanco, J. J., Pol, S. U., & Sim, F. J. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.03.017 · Cited by 56
Medina-Rodriguez, E. M., Bribián, A., Boyd, A. L., Palomo, V., Pastor, J., Lagares, A., Gil, C., Martı́nez, A., Williams, A., & de Castro, F. (2017) · Scientific Reports · doi:10.1038/srep43545 · Cited by 55
Laflamme, N., Cisbani, G., Préfontaine, P., Srour, Y., Bernier, J., St-Pierre, M.-K., Tremblay, M.-È., & Rivest, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00178 · Cited by 55
Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis
Gentile, A., Musella, A., Vito, F. D., Rizzo, F. R., Fresegna, D., Bullitta, S., Vanni, V., Guadalupi, L., Bassi, M. S., Buttari, F., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02197 · Cited by 55
Nellessen, A., Nyamoya, S., Zendedel, A., Slowik, A., Wruck, C. J., Beyer, C., Fragoulis, A., & Clarner, T. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00488-z · Cited by 57
Baror, R., Neumann, B., Segel, M., Chalut, K. J., Fancy, S. P. J., Schafer, D. P., & Franklin, R. J. M. (2019) · Glia · doi:10.1002/glia.23612 · Cited by 54
Oligodendrogenesis from neural stem cells: Perspectives for remyelinating strategies
Grade, S., Bernardino, L. I., & Malva, J. O. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.01.004 · Cited by 54
Riccardis, L. D., Buccolieri, A., Muci, M., Pitotti, E., Robertis, F. D., Trianni, G., Manno, D. E., & Maffia, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.007 · Cited by 56
Basu, R., & Sarma, J. D. (2018) · Journal of Biosciences · doi:10.1007/s12038-018-9811-0 · Cited by 54
Polyák, H., Galla, Z., Nánási, N., Cseh, E. K., Rajda, C., Veres, G., Spekker, E., Szabó, Á., Klivènyi, P., Tanaka, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030945 · Cited by 56
Caminero, A. B., Comabella, M., & Montalbán, X. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04484.x · Cited by 54
Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit
Wang, H., Li, C., Wang, H., Mei, F., Liu, Z., Shen, H., & Xiao, L. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1323-1 · Cited by 54
Nathoo, N., Yong, V. W., & Dunn, J. F. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.04.011 · Cited by 53
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis
Rivera, F. J., & Aigner, L. (2012) · Biological Research · doi:10.4067/s0716-97602012000300007 · Cited by 56
The effect of realistic geometries on the susceptibility‐weighted MR signal in white matter
Xu, T., Foxley, S., Kleinnijenhuis, M., Chen, W. C., & Miller, K. L. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26689 · Cited by 50
Khodanovich, M. Y., Pishchelko, A. O., Glazacheva, V., Pan, E. S., Евгеньевич, А. А., Светлик, М. В., Tyumentseva, Y., Anan’ina, T. V., & Yarnykh, V. L. (2019) · Cells · doi:10.3390/cells8101204 · Cited by 53
Jurevics, H., Hostettler, J., Muse, E. D., Sammond, D. W., Matsushima, G. K., Toews, A. D., & Morell, P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00310.x · Cited by 53
Self-citation
Metadata
- Authors
- Matsushima, G. K., & Morell, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Matsushima, Glenn K.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 11
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC8098267
- OpenAlex
- W2100904149
- Cited by
- 984
- References
- 45
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 42 · 2023: 50 · 2022: 58 · 2021: 48 · 2020: 55 · 2019: 75 · 2018: 59 · 2017: 65 · 2016: 39 · 2015: 58 · 2014: 39 · 2013: 53 · 2012: 40
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns011615-29, 5r01ns037815-05, 5r29ns035372-05)
- National Institute of Neurological Disorders and Stroke (NS37815, NS-11615, NS-35372)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cuprizone, demyelination, remyelination, oligodendrocyte apoptosis, microglia, myelin phagocytosis, oligodendrocyte precursor cells, myelin gene expression, C57BL/6 mice, copper chelators
- MeSH terms
- Animals, Central Nervous System, Chelating Agents, Cuprizone, Demyelinating Diseases, Mice, Inbred C57BL, Myelin Sheath, Oligodendroglia, Microglia, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
